$107.43 +0.39 (%) Johnson & Johnson - NYSE

Oct. 31, 2014 | 02:56 PM

Partner Headlines

  1. Johnson & Johnson Fairly Valued - I Will Bet on It

    GuruFocus | Oct. 30, 2014 | 12:26PM EST
  2. Ebola Vaccine Contenders

    Benzinga | Oct. 30, 2014 | 10:44AM EST
  3. Video: Facebook, Gilead Post Earnings After The Close

    IBD | Oct. 28, 2014 | 14:00PM EST
  4. Receptos Soars After Lead Drug Racks Up Another Win

    IBD | Oct. 28, 2014 | 11:46AM EST
  5. Gilead Rises Ahead Of Q3 Earnings As Rivals Wobble

    IBD | Oct. 27, 2014 | 15:38PM EST
  6. Procter & Gamble Co Shares Lower Following Management Change

    Benzinga | Oct. 23, 2014 | 13:42PM EST
  7. 3M the Cash Generation Machine in the Industrials Segment

    GuruFocus | Oct. 23, 2014 | 12:53PM EST
  8. Ebola Test To Begin In Jan.

    IBD | Oct. 22, 2014 | 18:53PM EST
  9. Drug ETFs Attractive Buys On Pullback

    Benzinga | Oct. 22, 2014 | 17:10PM EST
  10. Major Indexes End Win Streak; Super Micro Surges

    IBD | Oct. 22, 2014 | 16:24PM EST
  11. Worried? Picks Of Mr. Cautious, 80% In Stocks

    YCharts | Oct. 22, 2014 | 15:51PM EST
  12. Stocks Erase Modest Gains; Apple Flirts With Breakout

    IBD | Oct. 22, 2014 | 15:06PM EST
  13. Dividend Aristocrats In Focus Part 24: Consolidated Edison

    GuruFocus | Oct. 22, 2014 | 14:43PM EST
  14. #PreMarket Primer: Wednesday, October 22: Johnson & Johnson Develops Ebola Vaccine

    Benzinga | Oct. 22, 2014 | 08:13AM EST
  15. Celgene Reports More Good Crohn's Disease Data

    IBD | Oct. 21, 2014 | 11:32AM EST
  16. Bill Frels Comments on Johnson & Johnson

    GuruFocus | Oct. 20, 2014 | 16:14PM EST
  17. Celgene's Crohn's Disease Drug Hits Its Marks

    IBD | Oct. 20, 2014 | 11:16AM EST
  18. What Have We Really Lost?

    GuruFocus | Oct. 20, 2014 | 10:10AM EST
  19. Benzinga Weekly Preview: Earnings Season Is In Full Swing

    Benzinga | Oct. 19, 2014 | 10:19AM EST
  20. Illumina Helps Make Gene Sequencing Affordable

    IBD | Oct. 17, 2014 | 18:48PM EST
  21. #PreMarket Primer: Thursday, October 16: This Year's Spending Season Could Be Muted

    Benzinga | Oct. 16, 2014 | 07:40AM EST
  22. The Key Drivers For Johnson & Johnson

    GuruFocus | Oct. 15, 2014 | 19:10PM EST
  23. Was Celgene's Crohn's Disease Drug Worth The Price?

    IBD | Oct. 15, 2014 | 17:39PM EST
  24. Barclays: Johnson & Johnson's Q3 Could Be 'High Water Mark'

    Benzinga | Oct. 15, 2014 | 16:42PM EST
  25. J&J raises outlook on Q3 beat

    IBD | Oct. 14, 2014 | 18:51PM EST
  26. Making Money With Charles Payne: 10/14/14

    FoxBusiness | Oct. 14, 2014 | 18:00PM EST
  27. Johnson & Johnson Conference Call Highlights

    Benzinga | Oct. 14, 2014 | 15:21PM EST
  28. Deutsche Bank Says Gilead Sciences Stock Reaction Is Overdone

    Benzinga | Oct. 14, 2014 | 13:59PM EST
  29. J&J Earnings Beat; Olysio Chatter Hits Gilead

    IBD | Oct. 14, 2014 | 11:54AM EST
  30. Stocks Up, Whittle Early Gains; Skyworks Spikes On Guidance

    IBD | Oct. 14, 2014 | 10:42AM EST
  31. JPM Posts Mixed 3Q as Trading Rebounds

    FoxBusiness | Oct. 14, 2014 | 09:40AM EST
  32. J&J Worldwide Pharama Sales Growth YoY

    Benzinga | Oct. 14, 2014 | 07:55AM EST
  33. Earnings Scheduled For October 14, 2014

    Benzinga | Oct. 14, 2014 | 05:23AM EST
  34. Stocks To Watch For October 14, 2014

    Benzinga | Oct. 14, 2014 | 04:09AM EST
  35. Video: Intel Among Top 4 Earnings Reports Tuesday

    IBD | Oct. 13, 2014 | 16:26PM EST
  36. J&J's Alios BioPharma Reports Presented Positive Results of Anti-RSV Nucleoside Analog AL-8176

    Benzinga | Oct. 13, 2014 | 08:35AM EST
  37. Retail Sales Take the Stage, 3Q Earnings Rev Up

    FoxBusiness | Oct. 10, 2014 | 17:30PM EST
  38. Gilead's Hep C Combo Pill Harvoni Approved, Priced

    IBD | Oct. 10, 2014 | 15:13PM EST
  39. Making Money With Charles Payne: 10/08/14

    FoxBusiness | Oct. 9, 2014 | 18:00PM EST
  40. #PreMarket Primer: Wednesday, October 8: IMF Cuts Global Growth Prospects, Puts A Damper On Wall Street

    Benzinga | Oct. 8, 2014 | 08:19AM EST
  41. Health Care, Tech Names Offer Dividend Growth, Stability

    IBD | Oct. 3, 2014 | 18:29PM EST
  42. #PreMarket Primer: Friday, October 3: JP Morgan Suffers Largest Cyberattack Against A Financial Institution

    Benzinga | Oct. 3, 2014 | 07:03AM EST
  43. Will Gilead Sciences Score Healthy Gains For Investors?

    IBD | Oct. 2, 2014 | 13:03PM EST
  44. Sure Bets: Slow-Changing Industries for Long-Term Investors

    GuruFocus | Oct. 1, 2014 | 18:48PM EST
  45. Johnson & Johnson Falls On Bernstein Downgrade

    Benzinga | Oct. 1, 2014 | 15:09PM EST
  46. Stocks Sell Off On Europe Worries; Growth Names Slammed

    IBD | Oct. 1, 2014 | 15:04PM EST
  47. Why Mega-Cap Stocks Are Beating Broader Market

    YCharts | Oct. 1, 2014 | 12:02PM EST
  48. Benzinga's Top Downgrades

    Benzinga | Oct. 1, 2014 | 08:53AM EST
  49. Bernstein Downgrades Johnson & Johnson To Market Perform, Shares Drop

    Benzinga | Oct. 1, 2014 | 08:13AM EST
  50. J&J Moves Into Gilead's Turf

    IBD | Sep. 30, 2014 | 18:43PM EST
Trading Center